Infectious Disease / Microbiology Updates
6.65K subscribers
31 photos
3 videos
23 files
3.72K links
All the atest articles, research and news from worlds leading Infectious Disease Journals.

Discussion group
https://t.me/Professional_Medical_Discussion
Download Telegram
State-of-the-Art Review: Chagas Disease—an Enduring Challenge

https://academic.oup.com/cid/article/82/2/187/8497697?rss=1
[Profile] Reem Abu Shomar— championing water safety in Gaza
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00064-2/fulltext?rss=yes

As a Palestinian female scientist, Reem Abu Shomar experiences repeated trauma thinking of the war in Gaza. An expert in water safety and public health, Shomar spent more than two decades working in this sector in Gaza, and defended her PhD on water technology in September 2023, just weeks before her life and those of all she knew would be changed forever by the war. She is now based in Toronto, Canada, where she continues her public health and water safety research though collaboration with international partners.
[Correspondence] Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00009-5/fulltext?rss=yes

We thank Brenda A Warecki and colleagues for their thoughtful letter on our study on cefiderocol versus standard therapy for Gram-negative bacterial bloodstream infection.1 They question whether the outcome of patients randomly assigned to cefiderocol might have been more favourable if the type of metallo-β-lactamase (MBL) was determined at the initiation of therapy using a rapid molecular diagnostic test, with the implication that patients infected with organisms harbouring NDM genes should have been excluded from the trial.
[Correspondence] Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00008-3/fulltext?rss=yes

David L Paterson and colleagues recently evaluated cefiderocol versus standard-of-care therapy for hospital-acquired and health-care-associated bloodstream infections caused by Gram-negative bacilli.1 This was an international, open-label, parallel-group, randomised clinical trial. 250 patients received cefiderocol and 254 received standard-of-care treatment. Cefiderocol resulted in a non-inferior 14-day mortality compared with standard of care, even within the carbapenem-resistant subset. This interpretation places cefiderocol as effective treatment for Gram-negative bloodstream infections, regardless of the underlying carbapenemase mechanism.
[Comment] Peer review at The Lancet Infectious Diseases in 2025
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00079-4/fulltext?rss=yes

In this issue of The Lancet Infectious Diseases, the editorial team would like to thank all the researchers who peer reviewed for us in 2025. We express our gratitude to the 876 people from 82 countries who peer reviewed at least one article for us in the past year. We are particularly grateful to the peer reviewers who looked at more than one article and/or assessed several revisions. Without their expertise and constructive feedback, we would not be able to publish infectious disease research of the highest quality.
1
[Comment] Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00072-1/fulltext?rss=yes

Fernando Abad-Franch
[Newsdesk] Controversial HBV vaccine trial in Guinea-Bissau halted
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00075-7/fulltext?rss=yes

A US-funded study in Guinea-Bissau on the effects of neonatal hepatitis B virus vaccination has been suspended pending further review due to ethical concerns. Talha Burki reports.
[Newsdesk] People needing trachoma interventions at record low
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00073-3/fulltext?rss=yes

In January 2026, WHO reported that the number of people requiring interventions for trachoma had fallen below 100 million—a 94% reduction since 2002. Timothy Jesudason reports.